Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.

ABSTRACT:

Introduction

Chronic myeloid leukemia (CML) is a chronic disease with treatment-free remission (TFR) increasingly regarded as a feasible goal of treatment. However, various factors may influence adherence to international guidelines for CML management. This study aimed to compare the reporting of care between patients with CML and their treating doctors.

Methods

Parallel patient and physician online surveys were conducted between September 22, 2021, and March 15, 2022, which focused on the perceptions of 1882 adult patients with CML and 305 physicians regarding tyrosine kinase inhibitor (TKI) treatment options, monitoring and toxicities, TFR, and challenges faced.

Results

Among the enrolled patients, 69.9% received first-line imatinib treatment, 18.6% received nilotin

SUBMITTER: Chen H 

PROVIDER: S-EPMC10881939 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature